DO-BO

How Can Europe Move from Innovation Paradox to Powerhouse,  Cuno Moser?

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer engages with Swiss healthcare strategist Cuno Moser to explore Europe’s “innovation paradox” in healthcare. Despite its strengths in research, data quality, and clinical expertise, Europe struggles to transform pilot projects into scalable, reimbursable solutions. With over 27 fragmented reimbursement systems in the EU and in Switzerland, significant barriers impede progress in digital health, medtech, and AI-driven care. Beyond funding, challenges such as misaligned incentives, insufficient execution infrastructure, and flawed system design keep innovation stuck in “pilot purgatory.”

Looking ahead, while Europe may not lead in speed, it has the opportunity to excel in quality and trust. This could allow European health platforms to establish a competitive edge. If you’re involved in digital health, medtech, AI, or market access and find your solution stalled between a promising pilot and real-world scalability, this episode is a must-listen.

https://www.linkedin.com/feed/update/urn:li:activity:7437804838232453120/

Related

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]